170 related articles for article (PubMed ID: 33992491)
1. Adjuvant therapy and prognosis in uterine carcinosarcoma.
Chiang CY; Huang HJ; Chang WY; Yang LY; Wu RC; Wang CC; Tung HJ; Chao A; Lai CH
J Formos Med Assoc; 2021 Nov; 120(11):1977-1987. PubMed ID: 33992491
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of uterine carcinosarcoma: results of 94 patients.
Gokce ZK; Turan T; Karalok A; Tasci T; Ureyen I; Ozkaya E; Kose MF; Tulunay G
Int J Gynecol Cancer; 2015 Feb; 25(2):279-87. PubMed ID: 25611900
[TBL] [Abstract][Full Text] [Related]
5. Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma.
Matsuo K; Omatsu K; Ross MS; Johnson MS; Yunokawa M; Klobocista MM; Im DD; Bush SH; Ueda Y; Takano T; Blake EA; Hasegawa K; Baba T; Shida M; Satoh S; Yokoyama T; Machida H; Adachi S; Ikeda Y; Iwasaki K; Miyake TM; Yanai S; Nishimura M; Nagano T; Takekuma M; Takeuchi S; Pejovic T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
Gynecol Oncol; 2017 Apr; 145(1):78-87. PubMed ID: 28215838
[TBL] [Abstract][Full Text] [Related]
6. A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
Dickson EL; Vogel RI; Gehrig PA; Pierce S; Havrilesky L; Secord AA; Dottino J; Fader AN; Ricci S; Geller MA
Gynecol Oncol; 2015 Nov; 139(2):275-82. PubMed ID: 26348313
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and adjuvant therapy in uterine carcinosarcoma.
Wu TI; Hsu KH; Huang HJ; Hsueh S; Chou HH; Tsai CS; Ho KC; Chao A; Chang TC; Lai CH
Eur J Gynaecol Oncol; 2008; 29(5):483-8. PubMed ID: 19051818
[TBL] [Abstract][Full Text] [Related]
8. Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years.
Matsuo K; Ross MS; Yunokawa M; Johnson MS; Machida H; Omatsu K; Klobocista MM; Im DD; Satoh S; Baba T; Ikeda Y; Bush SH; Hasegawa K; Blake EA; Takekuma M; Shida M; Nishimura M; Adachi S; Pejovic T; Takeuchi S; Yokoyama T; Ueda Y; Iwasaki K; Miyake TM; Yanai S; Nagano T; Takano T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
Surg Oncol; 2019 Jun; 29():25-32. PubMed ID: 31196490
[TBL] [Abstract][Full Text] [Related]
9. Wilms' tumor 1 protein and estrogen receptor beta expression are associated with poor outcomes in uterine carcinosarcoma.
Guntupalli SR; Cao D; Shroff R; Gao F; Menias C; Stewart Massad L; Powell MA; Mutch DG; Thaker PH
Ann Surg Oncol; 2013 Jul; 20(7):2373-9. PubMed ID: 23344579
[TBL] [Abstract][Full Text] [Related]
10. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus.
Yamada SD; Burger RA; Brewster WR; Anton D; Kohler MF; Monk BJ
Cancer; 2000 Jun; 88(12):2782-6. PubMed ID: 10870061
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes in completely resected stage I to stage IV uterine carcinosarcoma with rhabdomyosarcoma differentiation.
Makker V; Kravetz SJ; Gallagher J; Orodel OP; Zhou Q; Iasonos A; DeLair D; Aghajanian C; Hensley ML
Int J Gynecol Cancer; 2013 Nov; 23(9):1635-41. PubMed ID: 24172099
[TBL] [Abstract][Full Text] [Related]
12. Multimodality adjuvant therapy and survival outcomes in stage I-IV uterine carcinosarcoma.
McEachron J; Heyman T; Shanahan L; Tran V; Friedman M; Gorelick C; Economos K; Singhal PK; Lee YC; Kanis MJ
Int J Gynecol Cancer; 2020 Jul; 30(7):1012-1017. PubMed ID: 32447295
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group.
Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
Int J Clin Oncol; 2016 Feb; 21(1):168-76. PubMed ID: 26084780
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma.
Şükür YE; Taşkın S; Varlı B; Ateş C; Güngör M; Ortaç F
Int J Clin Oncol; 2018 Feb; 23(1):114-120. PubMed ID: 28836024
[TBL] [Abstract][Full Text] [Related]
15. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
[TBL] [Abstract][Full Text] [Related]
16. Uterine carcinosarcoma: A 10-year single institution experience.
Terblanche L; Botha MH
PLoS One; 2022; 17(7):e0271526. PubMed ID: 35862371
[TBL] [Abstract][Full Text] [Related]
17. Improved survival with combination chemotherapy and external beam radiation therapy in uterine carcinosarcoma.
McEachron J; Chen YJ; Zhou N; Kao J; Gorelick C; Kanis MJ; Lee YC
Int J Gynecol Cancer; 2022 Nov; 32(11):1402-1409. PubMed ID: 36343971
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Treatment Modalities, Prognostic Factors, and Outcome of the Uterine Carcinosarcoma.
Kahramanoglu I; Demirkiran F; Turan H; Bese T; Cebi S; Ilvan S; Arvas M
J Obstet Gynaecol Can; 2021 Jan; 43(1):34-42. PubMed ID: 33041218
[TBL] [Abstract][Full Text] [Related]
19. Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery.
Matsuo K; Johnson MS; Im DD; Ross MS; Bush SH; Yunokawa M; Blake EA; Takano T; Klobocista MM; Hasegawa K; Ueda Y; Shida M; Baba T; Satoh S; Yokoyama T; Machida H; Ikeda Y; Adachi S; Miyake TM; Iwasaki K; Yanai S; Takeuchi S; Nishimura M; Nagano T; Takekuma M; Shahzad MMK; Pejovic T; Omatsu K; Kelley JL; Ueland FR; Roman LD
J Surg Oncol; 2018 Mar; 117(3):488-496. PubMed ID: 29044542
[TBL] [Abstract][Full Text] [Related]
20. Low-dose adjuvant vaginal cylinder brachytherapy for early-stage non-endometrioid endometrial cancer: recurrence risk and survival outcomes.
Smart A; Buscariollo D; Alban G; Buzurovic I; Cheng T; Pretz J; Krechmer B; King M; Lee L
Int J Gynecol Cancer; 2020 Dec; 30(12):1908-1914. PubMed ID: 32655012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]